The LATITUDE study confirmed that a long-acting injectable preparation of cabotegravir and rilpivirine is more effective than daily oral medication in preventing treatment failure in people with HIV who have difficulty taking their medication regularly[2]. The preparation is administered as an injection every four or eight weeks and can replace daily pills[1]. In the study, 94% of participants with long-term treatment with cabotegravir and rilpivirine in the high viral load group achieved viral suppression below 200 copies/mL[1]. The median time required to suppress the virus was 33 days[1]. The most common side effect was injection site reactions (60 percent), with only two participants discontinuing treatment due to this side effect[2]. The study included people with HIV who had difficulty adhering to daily treatment for a variety of reasons, including social barriers, side effects, and stigma[2]. The results of the study expanded the group of patients who can benefit from this long-term treatment[2].